Article

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastoma

2026-06-25

Abstract excerpt

<h4>ABSTRACT</h4> Metastatic neuroblastoma (NB), the most common pediatric extra-cranial solid tumor, has a cure rate of <50%. DNA-sequencing studies have demonstrated rare recurrent driver mutations at diagnosis, with the most common alterations detected in ALK-RAS-MAPK pathway. Activating ALK and RAS-MAPK mutations are associated with inferior outcome and are increased at relapse, and thus, represent therapeuti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4b1135de-56cb-5a3a-be96-9c2a18457a42
DOI: 10.64898/2026.06.24.734371

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaDOI 10.64898/2026.06.24.734371Read

Daraxonrasib (RMC-6236) is an effective targeted therapy for <i>RAS</i> -mutant neuroblastomaSemantic proximity Read

A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastomaSemantic proximity Read

NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.Semantic proximity Read

Dual Targeting of MAPK Signaling and Senescence-Associated Survival Pathways Overcomes Vincristine Resistance in Fusion-Negative RhabdomyosarcomaSemantic proximity Read

Targeting Pathways in Neuroblastoma: Advances in Treatment Strategies and Clinical OutcomesSemantic proximity Read

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination StrategiesSemantic proximity Read

Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid CancersSemantic proximity Read

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastomaSemantic proximity Read

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity Read

BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Semantic proximity Read

Limited antitumor activity of combined BET and MEK inhibition in neuroblastomaSemantic proximity Read

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by <i>NRAS</i> or <i>MEK</i> MutationsSemantic proximity Read